For full functionality of this page it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser Product Recall Management Best Practices Category Archives
US Flag
UK Flag Canada Flag

Category: Product Recall Management Best Practices

Jun
15

Expert Insight from Exponent

Exponent, Inc. is a multi-disciplinary engineering and scientific consulting firm that brings together more than 90 technical disciplines to solve engineering, science, regulatory, and business issues for its clients.

Continue Reading
Mar
27

Cosmetic Safety Legislation Threatens to Spur More Recalls

Cosmetic companies have been a target of consumer activists for years. Organizations like Environmental Working Group and Campaign for Safe Cosmetics have run campaigns that resulted in companies reformulating products or defending themselves publicly and in courtrooms across the country. As far as we can tell, these attacks won’t change; in fact, we can expect them to intensify as regulators tighten their control over the companies.

Continue Reading
Mar
19

Recalls During the COVID-19 Pandemic

First and foremost, we hope you and everyone close to you are well. We’re living through an unprecedented time and hopefully you’re able to find some calm and maintain connections. Like each of you, we’ve been working through the COVID-19 crisis, encouraging workers to follow the recommendations of federal, state and local health officials. But as crisis management professionals, we also can’t help but think about the long game.

Continue Reading
Nov
13

Product Recalls Stabilize, But an Upsurge is Expected

While U.S. product recalls were relatively flat from the second to third quarter, expect an upsurge in the weeks and months to come as regulators – under growing pressure from Congress and consumer groups – turn their attention to currently unregulated categories.  Part of that pressure on regulators is a result of past handling of product safety issues.

Continue Reading
Nov
07

It’s Official: Active Pharmaceutical Ingredient Makers in FDA’s Crosshairs

If there was any doubt whether the entire active pharmaceutical ingredient (API) industry is a target for continued FDA scrutiny, it should be gone. Donald Ashley, director of FDA’s Office of Compliance, talked about major concerns the agency has with the API industry at the Association for Accessible Medicines’ conference. As reported in an

Continue Reading